Introduction {#section5-1753466620937194}
============

Chronic obstructive pulmonary disease (COPD) represents a significant health burden and is currently the third leading cause of death worldwide.^[@bibr1-1753466620937194]^ Long-acting bronchodilators, including long-acting β2 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), are the mainstay of treatment for symptom management in patients with COPD. In recent years, LABA/LAMA fixed-dose combinations (FDCs) have increasingly been used to treat COPD due to greater improvements in lung function, symptom scores, and health status when compared with LABA or LAMA monotherapy.^[@bibr2-1753466620937194][@bibr3-1753466620937194][@bibr4-1753466620937194]--[@bibr5-1753466620937194]^ There is solid evidence showing that LAMAs are superior to LABAs with regards to exacerbation prevention.^[@bibr6-1753466620937194]^ However, the advantage of LABA/LAMA over LAMA in preventing exacerbations has not been consistently demonstrated, so the use of LABA/LAMA FDCs as initial treatment is currently guided by the level of symptoms but not the risk of exacerbations. According to the 2019 and 2020 revised Global Initiative for Chronic Obstructive Lung Disease (GOLD) reports, LAMA monotherapy is recommended as the initial choice of therapy for patients at high risk of COPD exacerbations (group C and D). LABA/LAMA FDC is an alternative choice for those with more severe symptoms. In addition, for patients with persistent exacerbations on long-acting bronchodilator monotherapy, escalation to LABA/LAMA is also recommended in current guidelines.^[@bibr7-1753466620937194]^ The currently available LABA/LAMA FDCs, including olodaterol/tiotropium, indacaterol/glycopyrronium, formoterol/aclidinium, and vilanterol/umeclidinium, are widely used to treat COPD patients. However, few studies have investigated whether these LABA/LAMA FDCs offer additional benefits over LAMA monotherapy in exacerbation prevention. Recently, a large randomized controlled trial demonstrated that combining tiotropium and olodaterol did not reduce exacerbation rates as much as expected compared with tiotropium alone.^[@bibr8-1753466620937194]^ Given the increased number of LABA/LAMA FDCs for clinical use in COPD patients, the initial choice of these agents or LAMA alone remains under debate in terms of exacerbation prevention. The aim of the current analysis was therefore to evaluate the comparative efficacy of LABA/LAMA FDCs and LAMA monotherapy in preventing exacerbations.

Methods {#section6-1753466620937194}
=======

Search strategy and eligibility criteria {#section7-1753466620937194}
----------------------------------------

We performed a systematic literature search to identify randomized controlled trials (RCTs) evaluating the efficacy and safety of long-acting bronchodilators for COPD using PubMed, EMBASE, Cochrane Library, and Trip databases for relevant studies published up to August 1, 2019. In addition, reference lists of the included studies were scanned, and experts and physicians in this field were also consulted. This systematic review was drafted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols (PRISMA-P) guidelines.^[@bibr9-1753466620937194]^ The inclusion criteria were: (a) patients with stable COPD according to the GOLD diagnostic criteria; (b) randomized controlled trials comparing LABA/LAMA FDCs and LAMAs; (c) at least 24 weeks of treatment duration; and (d) endpoints meeting any of our outcomes of interest (time to first exacerbation, rates of moderate to severe, severe and all exacerbations). We also included studies with subgroup analysis comparing LAMA/LABA FDCs with individual LAMA components.

Data extraction and risk of bias assessment {#section8-1753466620937194}
-------------------------------------------

The title and abstract of each study were independently assessed by three authors (C-YC, W-CC, and Y-FW) to confirm the eligibility for analysis, and any difference in opinion was resolved by consensus. Data from the included studies were independently extracted and checked by C-YC and Y-FW Two reviewers (C-YC and W-CC) independently assessed the risk of bias of the included studies according to the recommendations in the Cochrane Handbook for Systematic Reviews of Interventions 5.1. Disagreements were resolved by consensus or assessed by other authors (Y-PH and C-HH).

Outcomes of interest {#section9-1753466620937194}
--------------------

The outcomes of interest were the frequency of acute exacerbations (time to first exacerbation, rates of moderate to severe, severe and all exacerbations). Frequencies of exacerbations were also analyzed according to the treatment duration, high-risk *versus* low-risk populations, and tiotropium *versus* non-tiotropium groups.

Statistical analysis {#section10-1753466620937194}
--------------------

Studies were pooled using risk ratios (RRs) for dichotomous outcomes and hazard ratios (HRs) for time to event outcomes in random effect models, respectively.^[@bibr10-1753466620937194]^ A 95% confidence interval (CI) was set to determine statistical significance. Between-study heterogeneity assessed using the *I*^2^ test was considered to be moderate to high at a *p*-value \< 0.10 and *I*^2^ value \> 50%. Publication bias was examined using eyeballing, funnel plots and Egger's test. Sensitivity analyses were performed to assess the contribution of each study to the pooled estimate by excluding individual studies one at a time and recalculating the pooled HR estimates for the remaining studies (one-study-removed meta-analysis). For any three-arm trials (e.g. indacaterol/glycopyrronium *versus* glycopyrronium *versus* tiotropium), each pairwise comparison (i.e. indacaterol/glycopyrronium *versus* glycopyrronium, and indacaterol/glycopyrronium *versus* tiotropium) was used in the meta-analysis by dividing the sample size in half to match the total sample size when adding together. High-risk *versus* low-risk exacerbation patient groups were defined according to the previous exacerbation history (⩾1 *versus* no exacerbations) or lung function (⩾50% *versus* \<50% of forced expiratory volume in the first second) for the majority patients in the study. The meta-analysis was performed using Review Manager Software version 5.3 (Cochrane Library Software, Oxford, UK).

Results {#section11-1753466620937194}
=======

Study characteristics {#section12-1753466620937194}
---------------------

The relevant research and studies are shown in [Figure 1](#fig1-1753466620937194){ref-type="fig"}. Two articles reported different outcomes from the same patients group so only one was included for analysis.^[@bibr11-1753466620937194],[@bibr12-1753466620937194]^ Finally, a total of 19,369 patients were included in nine published articles from 2013 to 2018.^[@bibr8-1753466620937194],[@bibr12-1753466620937194][@bibr13-1753466620937194][@bibr14-1753466620937194][@bibr15-1753466620937194][@bibr16-1753466620937194][@bibr17-1753466620937194][@bibr18-1753466620937194]--[@bibr19-1753466620937194]^ Among these included articles, two compared indacaterol/glycopyrronium, glycopyrronium, and tiotropium; two compared tiotropium/olodaterol and tiotropium; two compared aclidinium/formoterol and aclidinium; one compared umeclidinium/vilanterol, umeclidinium, and tiotropium; one compared umeclidinium/vilanterol and tiotropium; and one compared glycopyrrolate/formoterol fumarate, glycopyrrolate, and tiotropium.

![Flow diagram of study identification.\
ICS, inhaled corticosteroids; LAMA, long-acting muscarinic antagonist.](10.1177_1753466620937194-fig1){#fig1-1753466620937194}

All the studies were RCTs and double-blinded, with a treatment period from 24 to 64 weeks. Three of the articles reported outcomes from two duplicate RCTs, and one of them reported outcomes of two trials separately.^[@bibr12-1753466620937194],[@bibr15-1753466620937194],[@bibr18-1753466620937194]^ We paired the LAMA/LABA FDCs and compared them with individual or different LAMA components in the studies including three or more comparators. The characteristics of the included studies are summarized in [Table 1](#table1-1753466620937194){ref-type="table"}.

###### 

Study characteristics of the included studies.

![](10.1177_1753466620937194-table1)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                   Study duration (weeks)   Number of patients   Treatment comparison/dose (µg)      Mean age\   Male\   Baseline FEV~1~\   COPD severity by lung function    Exacerbation risk by lung function   Exacerbation history in previous year   Exacerbation risk by previous AE
                                                                                                                                            (years)     (%)     % predicted                                                                                                                       
  ------------------------------------------------------- ------------------------ -------------------- ----------------------------------- ----------- ------- ------------------ --------------------------------- ------------------------------------ --------------------------------------- ----------------------------------
  Bateman *et al.*^[@bibr13-1753466620937194]^            26                       474                  Indacaterol 110/glycopyrronium 50   64.0        76.4    55.7               Moderate (63.8%) Severe (36.1%)   Low                                  0 (73.7%) 1 (19.5%) ⩾2 (6.8%)           Low

                                                                                   473                  Glycopyrronium 50                   64.3        77.2    55.1                                                                                                                              

                                                                                   480                  Tiotropium 18                       63.5        75.0    55.1                                                                                                                              

  Wedzicha *et al.*^[@bibr14-1753466620937194]^           64                       729                  Indacaterol 110/glycopyrronium 50   63.1        76.0    37.0               Severe (79.2%)\                   High                                 0 (1.5%) 1 (76.5%) ⩾2 (21.4%)           High
                                                                                                                                                                                   Very severe (20.8%)                                                                                            

                                                                                   740                  Glycopyrronium 50                   63.1        73.0    37.3                                                                                                                              

                                                                                   737                  Tiotropium 18                       63.6        75.0    37.4                                                                                                                              

  Decramer *et al.*^[@bibr15-1753466620937194]^ study 1   24                       212                  Umeclidinium 62.5/vilanterol 25     63.0        70.0    48.0               Moderate (48.0%)\                 High                                 0 (51.2%) ⩾1 (48.8%)                    Low
                                                                                                                                                                                   Severe (41.2%)\                                                                                                
                                                                                                                                                                                   Very severe (10.8%)                                                                                            

                                                                                   208                  Tiotropium 18                       62.6        67.0    47.8                                                                                                                              

  Decramer *et al.*^[@bibr15-1753466620937194]^ study 2   24                       217                  Umeclidinium 62.5/vilanterol 25     65.0        65.0    47.7               Moderate (43.9%)\                 High                                 0 (66.5%) ⩾1 (33.5%)                    Low
                                                                                                                                                                                   Severe (43.2%)\                                                                                                
                                                                                                                                                                                   Very severe (12.8%)                                                                                            

                                                                                   222                  Umeclidinium 125                    64.5        67.0    46.2                                                                                                                              

                                                                                   215                  Tiotropium 18                       65.2        71.0    47.4                                                                                                                              

  Maleki-Yazdi *et al*.^[@bibr16-1753466620937194]^       24                       454                  Umeclidinium 62.5/vilanterol 25     61.9        68.0    46.2               Moderate (41.4%)\                 High                                 N/A                                     N/A
                                                                                                                                                                                   Severe (45.6%)\                                                                                                
                                                                                                                                                                                   Very severe (12.9%)                                                                                            

                                                                                   451                  Tiotropium 18                       62.7        67.0    46.5                                                                                                                              

  Singh *et al.*^[@bibr17-1753466620937194]^              24                       385                  Aclidinium 400/formoterol 12        62.7        67.8    54.6               Moderate (59.2%)\                 Low                                  N/A                                     N/A
                                                                                                                                                                                   Severe (40.8%)                                                                                                 

                                                                                   385                  Aclidinium 400                      63.1        66.5    53.6                                                                                                                              

  Buhl *et al*.^[@bibr12-1753466620937194]^               52                       1029                 Tiotropium 5/olodaterol 5           63.8        71.2    49.3               Moderate (49.4%)\                 High                                 N/A                                     N/A
                                                                                                                                                                                   Severe (38.6%)\                                                                                                
                                                                                                                                                                                   Very severe (12.0%)                                                                                            

                                                                                   1033                 Tiotropium 5                        63.9        73.1    49.7                                                                                                                              

  Hanania *et al.*^[@bibr18-1753466620937194]^            52                       1035                 Glycopyrrolate 18/formoterol 9.6    62.7        54.3    43.4               Very severe (10.2%)               N/A                                  0 (83.3%)\                              Low
                                                                                                                                                                                                                                                          1 (9.5%) ⩾2 (7.2%)                      

                                                                                   888                  Glycopyrrolate 18                   62.8        55.9    42.6                                                                                                                              

                                                                                   450                  Tiotropium 18                       62.9        59.6    42.7                                                                                                                              

  D'Urzo *et al.*^[@bibr19-1753466620937194]^             52                       335                  Aclidinium 400/formoterol 12        64.2        50.1    53.2               Moderate (56.3%)\                 Low                                  0 (79.2%) ⩾1 (20.8%)                    Low
                                                                                                                                                                                   Severe (43.7%)                                                                                                 

                                                                                   337                  Aclidinium 400                      64.4        55.8    53.0                                                                                                                              

  Calverley *et al*.^[@bibr8-1753466620937194]^           52                       3939                 Tiotropium 5/olodaterol 5           66.5        71.0    44.6               N/A                               N/A                                  1 (55.7%) ⩾2 (44.3%)                    High

                                                                                   3941                 Tiotropium 5                        66.3        72.0    44.5                                                                                                                              
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AE, acute exacerbations; COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in the first second.

Risk of bias {#section13-1753466620937194}
------------

Risk of bias assessments for the included studies were performed by the review authors independently. Most of the studies had a low risk of bias as shown by sufficient evidence of random sequence generation, double blinding protocol, and complete outcome assessment ([Figure 2](#fig2-1753466620937194){ref-type="fig"}). However, an unclear risk of performance bias was found in four studies due to not mentioning the double dummy technique,^[@bibr13-1753466620937194],[@bibr14-1753466620937194],[@bibr17-1753466620937194],[@bibr18-1753466620937194]^ and detection bias may have occurred in two studies due to incomplete descriptions of the blinding of outcome assessments.^[@bibr12-1753466620937194],[@bibr17-1753466620937194]^

![Risk of bias graph: review authors' judgement about the risk of each item of bias presented as percentages across all included studies.](10.1177_1753466620937194-fig2){#fig2-1753466620937194}

Outcome assessments {#section14-1753466620937194}
-------------------

### Time to first exacerbation {#section15-1753466620937194}

Four publications (including five RCTs, *n* = 5293) reported the time to first exacerbation as the endpoint ([Figure 3](#fig3-1753466620937194){ref-type="fig"}). There was no statistical difference between the patients receiving LAMA/LABA FDCs compared with individual LAMAs (tiotropium, umeclidinium, and glycopyrronium). The HR for an exacerbation was 0.96 (95% CI 0.79--1.18; *p* = 0.71, *I*^2^ = 46%). Subgroup analyses according to different LAMAs (tiotropium and non-tiotropium), treatment duration (24 weeks and 52--64 weeks), and risk of exacerbations (by exacerbation history) were all not statistically significant ([Supplemental Figures S1](https://journals.sagepub.com/doi/suppl/10.1177/1753466620937194), [S2](https://journals.sagepub.com/doi/suppl/10.1177/1753466620937194), and [S3](https://journals.sagepub.com/doi/suppl/10.1177/1753466620937194)).

![Forrest plot comparing LABA/LAMA FDCs and LAMAs on time to first exacerbation.\
CI, confidence interval; FDC, fixed-dose combination; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.](10.1177_1753466620937194-fig3){#fig3-1753466620937194}

### Moderate-to-severe exacerbations {#section16-1753466620937194}

Moderate-to-severe exacerbation data were available in four articles (*n* = 10,791). Overall, 30.0% (1620/5389) of the patients receiving LABA/LAMA FDCs experienced moderate-to-severe exacerbations, compared with 31.7% (1714/5402) of the patients receiving LAMAs alone ([Figure 4](#fig4-1753466620937194){ref-type="fig"}). The RR was 0.96 (95% CI 0.90--1.03; *p* = 0.28, *I*^2^ = 16%), and no statistical difference was found. We then analyzed LABA/LAMA FDCs compared with different LAMAs (tiotropium and non-tiotropium), treatment duration (24 weeks and 52--64 weeks), and risk of exacerbations (by exacerbation history), but no statistically significant differences were found ([Supplemental Figures S4](https://journals.sagepub.com/doi/suppl/10.1177/1753466620937194), [S5](https://journals.sagepub.com/doi/suppl/10.1177/1753466620937194), and [S6](https://journals.sagepub.com/doi/suppl/10.1177/1753466620937194)).

![Forrest plot comparing LABA/LAMA FDCs and LAMAs with events of moderate-to-severe exacerbations.\
CI, confidence interval; FDC, fixed-dose combination; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.](10.1177_1753466620937194-fig4){#fig4-1753466620937194}

### Severe exacerbations {#section17-1753466620937194}

Only two publications (*n* = 9349) reported severe exacerbations as one of the endpoints. There was no statistical difference between the LABA/LAMA FDCs and LAMA groups in terms of severe exacerbations \[9.9% (460/4669) *versus* 10.8% (504/4680), respectively\], with an RR of 0.92 (95% CI 0.81--1.03, *p* = 0.15, *I*^2^ = 0%) ([Figure 5](#fig5-1753466620937194){ref-type="fig"}).

![Forrest plot comparing LABA/LAMA FDCs and LAMAs with events of severe exacerbations.\
CI, confidence interval; FDC, fixed-dose combination; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.](10.1177_1753466620937194-fig5){#fig5-1753466620937194}

### All exacerbations {#section18-1753466620937194}

The incidence of all exacerbations from six articles (including 9 RCTs, *n* = 7941) was lower in those treated with LABA/LAMA FDCs than in those treated with LAMAs \[24.0% (996/4148) *versus* 26.1% (991/3799), respectively\], with an RR of 0.92 (95% CI 0.86--1.00; *p* = 0.04, *I*^2^ = 0%) ([Figure 6](#fig6-1753466620937194){ref-type="fig"}). Subgroup analyses showed similar efficacy in those treated with LABA/LAMA FDCs compared with those treated with different LAMAs, but slight superiority was demonstrated in those with a longer treatment duration (52--64 weeks) (RR, 0.92; 95% CI 0.85--1.00; *p *= 0.04) ([Supplemental Figures S7](https://journals.sagepub.com/doi/suppl/10.1177/1753466620937194) and [S8](https://journals.sagepub.com/doi/suppl/10.1177/1753466620937194)). Other analyses according to the risk of exacerbations (high-risk *versus* low-risk, stratified by exacerbation history or lung function), demonstrated a lower rate of all exacerbations only in the high-risk population stratified by exacerbation history (RR, 0.85; 95% CI 0.74--0.98; *p *= 0.03) ([Supplemental Figures S9](https://journals.sagepub.com/doi/suppl/10.1177/1753466620937194) and [S10](https://journals.sagepub.com/doi/suppl/10.1177/1753466620937194)).

![Forrest plot comparing LABA/LAMA FDCs and LAMAs with events of all exacerbations.\
CI, confidence interval; FDC, fixed-dose combination; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.](10.1177_1753466620937194-fig6){#fig6-1753466620937194}

Discussion {#section19-1753466620937194}
==========

**The results of this meta-analysis demonstrated that** LABA/LAMA FDCs were marginally beneficial in the prevention of all exacerbations compared with LAMA monotherapy in COPD patients. According to the revised GOLD reports, LAMA monotherapy is preferred as the initial treatment choice in group C and D COPD patients, and LABA/LAMA FDCs are an alternative choice for those with more symptoms.^[@bibr7-1753466620937194]^ Escalation to LABA/LAMA is also recommended for patients with persistent exacerbations on LAMA monotherapy. Nevertheless, the 2019 updated National Institute for Health and Clinical Excellence (NICE) guidelines recommended LAMA+LABA dual therapy, but not monotherapy, as the preferred initial treatment in stable COPD patients who remain breathless or have exacerbations despite optimal non-pharmacological management and after using a short-acting bronchodilator.^[@bibr20-1753466620937194]^ The NICE guidelines also state that LAMA/LABA dual therapy provides the greatest benefit to overall quality of life compared with monotherapy, and that dual therapy is better than other inhaled treatments for many individual outcomes (such as reducing the risk of moderate-to-severe exacerbations) and is the most cost-effective option. Nevertheless, the currently available evidence is not consistent with regards to whether LABA/LAMA combination therapy is more effective than LAMA monotherapy in preventing exacerbations.

Previous meta-analyses have focused on comparisons of LABA/LAMA combinations and LAMA monotherapy. One meta-analysis conducted by Rodrigo *et al.* demonstrated greater efficacy and comparable safety profiles with LABA/LAMA combinations *versus* LAMAs. However, the COPD exacerbation rate was not reported due to insufficient data.^[@bibr21-1753466620937194]^ Rogliani *et al*. assessed the evidence for LABA/LAMA FDCs in the treatment of COPD. They analyzed trial results of the available LABA/LAMA FDCs and found that only indacaterol/glycopyrronium demonstrated superiority to glycopyrronium, but that there was no statistically significant difference *versus* tiotropium.^[@bibr22-1753466620937194]^

Oba *et al.* conducted a comprehensive Cochrane review of different groups of inhalers (including LABA/LAMA combinations and LAMA monotherapy) in patients with moderate-to-severe COPD. They analyzed eight studies comparing different LABA/LAMA combinations and LAMA monotherapy, and demonstrated no statistical differences in terms of severe exacerbations \[odds ratio (OR) 0.90; 95% CI 0.59--1.36; *p* = 0.61\] and moderate-to-severe exacerbations (OR 0.96, CI 0.75--1.23; *p* = 0.77).^[@bibr23-1753466620937194]^ Although this finding is consistent with our results, Oba's review enrolled two studies with LABA/LAMA combinations in two separate inhalers and one study which was a 12-week study that was inappropriate to evaluate exacerbation outcomes. In addition, the largest DYNAGITO trial was not included for analysis in their review.

Farne *et al*. reviewed 10 trials comparing tiotropium plus a LABA to tiotropium or a LABA alone and concluded that adding tiotropium to a LABA reduced exacerbations, but that adding a LABA to tiotropium did not.^[@bibr24-1753466620937194]^ Another comprehensive systematic review reported by Halpin *et al*. demonstrated that tiotropium was beneficial in reducing the risk of exacerbations compared with other maintenance treatments. Their analysis showed that tiotropium provided similar efficacy to glycopyrronium and a LABA/LAMA FDC (glycopyrronium/indacaterol), although not all studies were sufficiently powered to demonstrate differences in exacerbation outcomes.^[@bibr25-1753466620937194]^ However, the large DYNAGITO trial reported that a combination of tiotropium and olodaterol failed to reduce the exacerbation rate as expected when compared with tiotropium alone.^[@bibr8-1753466620937194]^ Given the conflicting results, we stratified and analyzed different LAMAs as tiotropium and non-tiotropium. Our analysis showed that exacerbation events in those receiving LAMA/LABA FDCs were not significantly different compared with those receiving tiotropium or non-tiotropium therapy.

In the current study, we also compared LABA/LAMA FDC and LAMA therapy in patients grouped by the risk of exacerbations and treatment duration. We analyzed the COPD patients with a high or low risk of exacerbations in the studies according to lung function or previous exacerbation history. Our results demonstrated that only the incidence of all exacerbation (but not severe or moderate to severe exacerbation) events was lower in the LABA/LAMA FDCs for COPD patients with a history of previous exacerbation. However, this result was from the SPARK study in which most of the patients had a previous history of exacerbation (DYNAGITO study did not provide outcomes of all exacerbation).^[@bibr14-1753466620937194]^ In addition, LABA/LAMA FDCs showed a small benefit in the incidence of all exacerbation events for those with a longer treatment period (52--64 weeks compared with 24--26 weeks), probably due to the long-term effects of LABA/LAMA combination therapy in terms of lung function improvements.

The GOLD reports recommend escalating to LABA/LAMA treatment for patients with persistent dyspnea or exacerbations on long-acting bronchodilator monotherapy. This escalation strategy is supported in part by this systematic review, in that LABA/LAMA FDCs may provide better efficacy in the prevention of all exacerbations compared to LAMA monotherapy, although the incremental benefit was small.

There are several limitations to this study. First, the results of this meta-analysis could not indicate differences between the various LABA/LAMA FDCs and LAMAs (although we stratified the LAMA group by tiotropium and non-tiotropium), and their efficacy may not be exactly the same. Second, assessments of the high- and low-risk patients in the included studies were not consistent, even though we stratified the majority of the study patients by lung function or previous exacerbation history. Third, exacerbation type (requiring antibiotic or systemic steroid therapy) was not analyzed due to insufficient data in the included studies.

In conclusion, our meta-analysis suggests that LAMA/LABA FDCs produce a small benefit in the prevention of all exacerbations compared to LAMA monotherapy, but similar efficacy in terms of time to first exacerbation, the rate of moderate-to-severe, and severe exacerbations. In addition to greater improvements in lung function, symptom scores, and health status, our findings provide evidence that LABA/LAMA FDCs are also better than LAMA monotherapy in terms of all exacerbation prevention and could be considered as the first-line treatment for COPD patients, especially in those with a history of previous exacerbations.
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